Tonix Pharmaceuticals Announces Acceptance of Three Abstracts to be Presented at the 2015 ACR/ARHP Annual Meeting

Tonix Pharmaceuticals Holding Corp.

("Tonix"), which is developing next-generation medicines for fibromyalgia, post-traumatic stress disorder, and episodic tension-type headache, announced today that three of its scientific abstracts have been accepted for presentation at the 2015 American College of Rheumatology / Association of Rheumatology Health Professionals Annual Meeting to be held November 7-11, 2015, in San Francisco, CA. The abstract and presentation details are as follows: Title: "Relationship of Sleep Quality and Fibromyalgia Outcomes in a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study of Bedtime, Rapidly Absorbed, Sublingual Cyclobenzaprine (TNX-102 SL)." Authors: Harvey Moldofsky, R Michael Gendreau, Daniel J. Clauw, Judith Gendreau, Benjamin Vaughn, Bruce Daugherty, Amy Forst, Gregory Sullivan and Seth Lederman Date & Time: Tuesday, November 10, 2015, 9:00 – 11:00 am Location: ACR Poster Session C Number: 2307 Title: "Responder Compared to Mean Change Analyses in a Fibromyalgia Phase 2b Clinical Study of Bedtime Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL)." Authors: R Michael Gendreau, Daniel J. Clauw, Judith Gendreau, Bruce Daugherty and Seth Lederman Date & Time: Tuesday, November 10, 2015, 9:00 – 11:00 am Location: ACR Poster Session C Number: 2308 Title: "Bedtime, Rapidly Absorbed Sublingual Cyclobenzaprine (TNX-102 SL) for the Treatment of Fibromyalgia: Results of a Phase 2b Randomized, Double-Blind, Placebo-Controlled Study." Authors: Seth Lederman, R Michael Gendreau, Daniel J. Clauw, Lesley M. Arnold, Judith Gendreau, Bruce Daugherty and Amy Forst Date & Time: Tuesday, November 10, 2015, 9:00 – 11:00 am Location: ACR Poster Session C Number: 2309